Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCE | Q02156 | 12/20 | 0.48 |
| ▸ | PRKCB | P05771 | 12/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 12/20 | 0.48 |
| ▸ | PRKCA | P17252 | 11/20 | 0.48 |
| ▸ | PRKCH | P24723 | 7/20 | 0.48 |
| ▸ | ELANE | P08246 | 3/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 4/20 | 0.33 |
| ▸ | PRKACA | P17612 | 2/20 | 0.33 |
| ▸ | PRKACG | P22612 | 2/20 | 0.33 |
| ▸ | PRKACB | P22694 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17349989 | 0.93 | PRKCB (0.40) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17349896 | 0.92 | PRKCB (0.40) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17349887 | 0.92 | PRKCB (0.40) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17349891 | 0.91 | PRKCB (0.41) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17349877 | 0.91 | PRKCB (0.40) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17349765 | 0.88 | PRKCB (0.40) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17349758 | 0.88 | PRKCA (0.43) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17337512 | 0.87 | PRKCB (0.35) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17337516 | 0.87 | PRKCB (0.35) | PRKCEPRKCBPRKCDPRKCAPRKCH | |
| SCHEMBL17349895 | 0.87 | ALDH1A1 (0.37) | PRKCEPRKCBPRKCDPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361107-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361107-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | SI, ALPI, GAA | PRKCE 2867/4885PRKCB 3762/4885PRKCD 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.